Halozyme Therapeutics Inc.
HALO
Market Cap$6.51B
Close$
$57.63
9.1% upside
Current Fair Value
9.1% upsideUndervalued by 9.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.51 Billion |
|---|---|
| Enterprise Value | $7.84 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $3.5 |
| Beta | 1.19 |
| Outstanding Shares | 123,215,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 13.41 |
|---|---|
| PEG | 24.95 |
| Price to Sales | 6.6 |
| Price to Book Ratio | 17.6 |
| Enterprise Value to Revenue | 7.23 |
| Enterprise Value to EBIT | 12.82 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 3.13 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley